Batavia partners in consortium to develop vaccine against Rift Valley fever 

Batavia Biosciences is proud to be a key partner in an important initiative aimed at combating the deadly Rift Valley fever. We are thrilled to share that as part of the consortium working alongside esteemed partners such as Wageningen Bioveterinary Research, Bunyavax BV, CR2O BV, University of Veterinary Medicine Hannover, and Integrum Scientific, LLC, we are stepping up our efforts to bring a protective vaccine to East Africa, where Rift Valley fever is endemic.
Batavia Biosciences - Favicon

Batavia Biosciences is proud to be a key partner in an important initiative aimed at combating the deadly Rift Valley fever. We are thrilled to share that as part of the consortium working alongside esteemed partners such as Wageningen Bioveterinary Research, Bunyavax BV, CR2O BV, University of Veterinary Medicine Hannover, and Integrum Scientific, LLC, we are stepping up our efforts to bring a protective vaccine to East Africa, where Rift Valley fever is endemic.

Batavia’s role as consortium partner

Our role in this endeavor is pivotal. At Batavia, we strive to reduce human suffering from infectious disease by helping improve vaccine affordability and availability around the world. Therefore, we have specialized in developing highly intensified manufacturing processes, leveraging our cutting-edge HIP-Vax® platform to create vaccines with a low cost of goods. As a consortium partner, our primary focus is on developing a scalable manufacturing process that can be rapidly scaled-up in the event of an outbreak. Furthermore, we are honored to take on the responsibility of manufacturing the clinical material for the Phase I and IIa trials planned for East Africa.

This initiative is a significant milestone in our ongoing battle against infectious diseases, particularly Rift Valley fever. The project, generously supported with up to US$25.9 million in funding from CEPI and backed by the European Union’s Horizon Europe program, will accelerate the development of a much-needed protective vaccine in East Africa.

Rift Valley fever: A climate-driven disease with epidemic potential

Rift Valley fever is a potentially lethal virus that can be transmitted to humans through mosquito bites or contact with infected livestock. With climate change increasing the risk of RVF outbreaks, the need for a protective human vaccine has never been more urgent. As a ‘One Health’ priority, the development of safe and effective human vaccines for RVF is crucial, and we are committed to playing our part in this vital endeavor.

Together with our esteemed partners and the support of CEPI and the European Union, we are determined to make a difference in the fight against Rift Valley fever.

Read the full press release for more details: CEPI expands partnership with Wageningen Bioveterinary Research to advance clinical trials of Rift Valley fever vaccine in affected countries – CEPI

Related

Viral Vector Production Guide

Bringing a new viral vector-based therapy from lab to market? This resource guides you through the complexities of viral vector development, scale-up, and cGMP manufacturing.

Low-cost viral vector manufacturing

High-throughput screening for viral vectors

Viral vector manufacturing

Thermostable viral envelope protein formulation

Maximizing protein expression